Cargando…

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA(1c) and Insulin Use: An Analysis From the FIDELIO-DKD Study

OBJECTIVE: Finerenone significantly improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial. We explored whether baseline HbA(1c) level and insulin trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rossing, Peter, Burgess, Ellen, Agarwal, Rajiv, Anker, Stefan D., Filippatos, Gerasimos, Pitt, Bertram, Ruilope, Luis M., Gillard, Pieter, MacIsaac, Richard J., Wainstein, Julio, Joseph, Amer, Brinker, Meike, Roessig, Lothar, Scott, Charlie, Bakris, George L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2022
Materias:	Emerging Therapies: Drugs and Regimens
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271031/ https://www.ncbi.nlm.nih.gov/pubmed/35061867 http://dx.doi.org/10.2337/dc21-1944

Ejemplares similares

Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials
por: Flack, John M., et al.
Publicado: (2023)

Generalizability of FIGARO‐DKD and FIDELIO‐DKD Trial Criteria to the US Population Eligible for Finerenone
por: Chiu, Nicholas, et al.
Publicado: (2022)

Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
por: Rossing, Peter, et al.
Publicado: (2021)

Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results
por: Agarwal, Rajiv, et al.
Publicado: (2021)

Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study
por: Ruilope, Luis M, et al.
Publicado: (2022)

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
por: Filippatos, Gerasimos, et al.
Publicado: (2021)

Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2022)

Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2021)

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2020)

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis
por: van den Berg, Paul, et al.
Publicado: (2021)

Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA(1c), in Patients With Type 2 Diabetes
por: Ali, Ali Muhammed, et al.
Publicado: (2020)

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
por: Agarwal, Rajiv, et al.
Publicado: (2021)

Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
por: Ruilope, Luis M., et al.
Publicado: (2022)

Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis
por: Pitt, Bertram, et al.
Publicado: (2022)

Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis
por: Filippatos, Gerasimos, et al.
Publicado: (2023)

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use
por: Rossing, Peter, et al.
Publicado: (2022)

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
por: Rossing, Peter, et al.
Publicado: (2021)

Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

The FIDELIO Study Podcast
por: Toto, Robert, et al.
Publicado: (2022)

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
por: Rossing, Peter, et al.
Publicado: (2022)

A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease
por: Agarwal, Rajiv, et al.
Publicado: (2022)

Correction to: The FIDELIO Study Podcast
por: Toto, Robert, et al.
Publicado: (2022)

Effect of finerenone on the occurrence of vision‐threatening complications in patients with non‐proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR)
por: Rossing, Peter, et al.
Publicado: (2022)

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
por: Kolkhof, Peter, et al.
Publicado: (2022)

Fidelio /
por: Beethoven, Ludwig van, 1770-1827
Publicado: (1985)

Finerenone for chronic kidney disease associated with type 2 diabetes with albuminuria
Publicado: (2023)

Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis
por: Rosas, Sylvia E., et al.
Publicado: (2023)

Fidelio Ponce
por: Sánchez, Juan
Publicado: (1985)

Randomized Outpatient Trial of Single- and Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors
por: Castle, Jessica R., et al.
Publicado: (2018)

Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Study
por: Klubo-Gwiezdzinska, Joanna, et al.
Publicado: (2018)

Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies
por: Peters, Anne L., et al.
Publicado: (2020)

Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6–17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial
por: Danne, Thomas, et al.
Publicado: (2020)

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial
por: Rosenstock, Julio, et al.
Publicado: (2020)

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
por: Perkovic, Vlado, et al.
Publicado: (2020)

Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
por: Wexler, Deborah J., et al.
Publicado: (2019)

The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes
por: van Raalte, Daniël H., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rk91t74hpt8gb531eufg6dqekb